U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. Drug Safety and Availability
  4. Postmarket Drug Safety Information for Patients and Providers
  5. Nizoral (ketoconazole) Information
  1. Postmarket Drug Safety Information for Patients and Providers

Nizoral (ketoconazole) Information

Nizoral (ketoconazole) is an antifungal drug indicated for the treatment of the following fungal infections when alternatives are not available or not tolerated: blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. Nizoral tablets should not be used for fungal meningitis because it penetrates poorly into the cerebrospinal fluid. 

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program using the contact information at the bottom of this page.

 

Related Information

Regulatory History and Labeling from Drugs@FDA

Back to Top